Literature DB >> 6139619

Detection of micrometastases in patients with primary breast cancer.

W H Redding, R C Coombes, P Monaghan, H M Clink, S F Imrie, D P Dearnaley, M G Ormerod, J P Sloane, J C Gazet, T J Powles.   

Abstract

An immunocytochemical method was used to screen smears obtained at primary surgery from multiple bone-marrow sites in 110 patients with breast cancer; at this time other techniques did not reveal metastases. Tumour cells were detected in the bone-marrow of 31 (28%) patients. The number of cells detected ranged from 1 to greater than 500; none was detected in conventionally stained smears. Patients in whom conventional criteria indicated a very poor prognosis seemed more likely to have such micrometastases. A further follow-up period is required to determine whether patients with micrometastases relapse earlier than those in whom no tumour cells are demonstrable.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6139619     DOI: 10.1016/s0140-6736(83)91150-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  46 in total

1.  Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis.

Authors:  G Delsol; T Al Saati; K C Gatter; J Gerdes; R Schwarting; P Caveriviere; F Rigal-Huguet; A Robert; H Stein; D Y Mason
Journal:  Am J Pathol       Date:  1988-01       Impact factor: 4.307

2.  Reverse transcriptase/polymerase chain reaction analysis of parathyroid hormone-related protein for the detection of tumor cell dissemination in the peripheral blood and bone marrow of patients with breast cancer.

Authors:  G G Wulf; B Jürgens; T Liersch; W Gatzemeier; H Rauschecker; C Buske; M Hüfner; W Hiddemann; B Wörmann
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies.

Authors:  G Schlimok; I Funke; B Holzmann; G Göttlinger; G Schmidt; H Häuser; S Swierkot; H H Warnecke; B Schneider; H Koprowski; G Riethmüller
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

4.  Adjuvant questions.

Authors:  D Brinkley
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-09

Review 5.  Circulating tumor cells: from bench to bedside.

Authors:  Marija Balic; Anthony Williams; Henry Lin; Ram Datar; Richard J Cote
Journal:  Annu Rev Med       Date:  2012-10-18       Impact factor: 13.739

6.  Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C.

Authors:  G Francini; R Petrioli; A Aquino; S Gonnelli
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.

Authors:  G Bonadonna; P Valagussa; A Rossi; G Tancini; C Brambilla; M Zambetti; U Veronesi
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

8.  The value of bone marrow examination for tumor staging in breast cancer.

Authors:  C Manegold; B Krempien; M Kaufmann; K Schwechheimer; G Schettler
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

9.  Immunomagnetic enrichment and detection of isolated tumor cells in bone marrow of patients with epithelial malignancies.

Authors:  Martin R Weihrauch; Edmund Skibowski; Andreas Draube; Andrea Geller; Hans Tesch; Volker Diehl; Heribert Bohlen
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

10.  Detection of occult bone marrow micrometastases in patients with operable lung carcinoma.

Authors:  R J Cote; E J Beattie; B Chaiwun; S R Shi; J Harvey; S C Chen; A E Sherrod; S Groshen; C R Taylor
Journal:  Ann Surg       Date:  1995-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.